1. Home
  2. LBTYA vs CRSP Comparison

LBTYA vs CRSP Comparison

Compare LBTYA & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LBTYA
  • CRSP
  • Stock Information
  • Founded
  • LBTYA 2004
  • CRSP 2013
  • Country
  • LBTYA Bermuda
  • CRSP Switzerland
  • Employees
  • LBTYA N/A
  • CRSP N/A
  • Industry
  • LBTYA Cable & Other Pay Television Services
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • LBTYA Telecommunications
  • CRSP Health Care
  • Exchange
  • LBTYA Nasdaq
  • CRSP Nasdaq
  • Market Cap
  • LBTYA 3.6B
  • CRSP 3.4B
  • IPO Year
  • LBTYA N/A
  • CRSP 2016
  • Fundamental
  • Price
  • LBTYA $9.31
  • CRSP $36.28
  • Analyst Decision
  • LBTYA Strong Buy
  • CRSP Buy
  • Analyst Count
  • LBTYA 3
  • CRSP 19
  • Target Price
  • LBTYA $19.33
  • CRSP $73.47
  • AVG Volume (30 Days)
  • LBTYA 2.0M
  • CRSP 2.1M
  • Earning Date
  • LBTYA 05-02-2025
  • CRSP 05-06-2025
  • Dividend Yield
  • LBTYA N/A
  • CRSP N/A
  • EPS Growth
  • LBTYA N/A
  • CRSP N/A
  • EPS
  • LBTYA N/A
  • CRSP N/A
  • Revenue
  • LBTYA $4,421,800,000.00
  • CRSP $37,675,000.00
  • Revenue This Year
  • LBTYA $4.47
  • CRSP $51.35
  • Revenue Next Year
  • LBTYA N/A
  • CRSP $282.16
  • P/E Ratio
  • LBTYA N/A
  • CRSP N/A
  • Revenue Growth
  • LBTYA 32.44
  • CRSP N/A
  • 52 Week Low
  • LBTYA $9.19
  • CRSP $30.04
  • 52 Week High
  • LBTYA $21.56
  • CRSP $67.88
  • Technical
  • Relative Strength Index (RSI)
  • LBTYA 28.75
  • CRSP 49.25
  • Support Level
  • LBTYA $9.19
  • CRSP $33.03
  • Resistance Level
  • LBTYA $11.11
  • CRSP $39.38
  • Average True Range (ATR)
  • LBTYA 0.28
  • CRSP 1.76
  • MACD
  • LBTYA -0.13
  • CRSP -0.09
  • Stochastic Oscillator
  • LBTYA 9.11
  • CRSP 53.12

About LBTYA Liberty Global Ltd.

Liberty Global is a holding company with interests in several telecom companies in the UK, the Netherlands, Belgium, Switzerland, Ireland, and Slovakia. Liberty owns the main cable network in each of these geographies, and has pursued a strategy since 2016 to merge or partner with mobile-network operators to be able to offer converged services. Liberty also owns minority stakes in other media, entertainment, and cloud companies.

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics AG is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Share on Social Networks: